Company intelligence / Profile preview
ACM Biolabs
Singapore, Singaporeacmbiolabs.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company’s lead asset, ACM‑001, uses polymersomes to deliver a SARS-CoV‑2 beta variant antigen and has entered Phase I human studies via both intranasal and intramuscular administration. The company continues to build its internal pipeline and advance medicines with partners[5][6].
- Therapeutic areas
- OtherInfectious Diseases
- Modalities
- Vaccines (prophylactic and therapeutic)Immune modulatorsAntibodies
- Industry
- Biotech
02
Drug pipeline
10 assets9 more assets in the full pipeline.
Beyond the preview
Go deeper on ACM Biolabs.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACM Biolabs.